4,4'-(2-phenylprop-1-ene-1,1-diyl)diphenol

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 4,4'-(2-phenylprop-1-ene-1,1-diyl)diphenol
• 英文别名: 4-[1-(4-Hydroxyphenyl)-2-phenylprop-1-enyl]phenol
• 化学式: C₂₁H₁₈O₂
• 分子量: 302.373
• InChiKey: VGWVLJXJHQENDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4,4'-(2-phenylprop-1-ene-1,1-diyl)diphenol 在 N-溴代丁二酰亚胺(NBS) 、 sodium hydride 作用下， 以 四氢呋喃 、 四氯化碳 为溶剂， 反应 6.0h， 生成 4,4-bis(4-hydroxyphenyl)-3-phenylbut-3-enenitrile
  参考文献：
  名称：

  TRIPHENYLETHYLENE COMPOUNDS AND USES THEREOF

  摘要：

  描述了三苯乙烯化合物作为双重芳香化酶抑制剂和选择性雌激素受体调节剂。还描述了使用所述三苯乙烯化合物或其药物制剂治疗乳腺癌患者和乳腺癌合并骨质疏松症患者的方法。

  公开号：

  US20170144975A1
• 作为产物：
  描述：

  1-(4-methoxyphenyl)-2-phenylpropan-1-one 在 三溴化硼 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 72.0h， 生成 4,4'-(2-phenylprop-1-ene-1,1-diyl)diphenol
  参考文献：
  名称：

  Investigations on Estrogen Receptor Binding. The Estrogenic, Antiestrogenic, and Cytotoxic Properties of C2-Alkyl-Substituted 1,1-Bis(4-hydroxyphenyl)-2-phenylethenes

  摘要：

  C2-Alkyl-substituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes were synthesized and assayed for estrogen receptor binding in a competition experiment with radiolabeled estradiol ([H-3]-E-2) using calf uterine cytosol. The relative binding affinity decreased with the length of the side chain R = H (3a: 35.2%) > Me (3b: 32.1%) > Et (3c: 6.20%); CH2CF3 (3d: 5.95%) > n-Pr (3e: 2.09%) > Bu (3f: 0.62%). Agonistic and antagonistic effects were evaluated in the luciferase assay with MCF-7-2a cells stably transfected with the plasmid ERE(wtc)luc. All compounds showed high antiestrogenic activity without significant agonistic potency. The comparison of the IC50 values for the inhibition of E2 (1 nM) documented the dependence of the antagonistic effects on the kind of the side chain: 3a (IC50 = 150 nM), 3b (IC50 = 30 nM), and 3f (IC50 = 500 nM) were weak antagonists, while 3c (IC50 = 15 nM), 3d (IC50 = 9 nM), and 3e (IC50 = 50 nM) were full antiestrogens and antagonized the effect of E2 completely. The most active compound 3d possessed the same antagonistic potency as 4-hydroxytamoxifen (40HT: IC50 = 7 nM) without bearing a basic side chain. 3d as well as all other 1,1-bis(4-hydroxyphenyl)-2-phenylalkenes were not able to influence the proliferation of hormone dependent MCF-7 cells despite the antagonistic mode of action. In this assay tamoxifen (TAM) and 40HT reduced the cell growth concentration dependent up to T/C-corr = 15% and 25%, respectively.

  DOI：

  10.1021/jm0209230

文献信息

• TRIPHENYLETHYLENE COMPOUNDS AND USES THEREOF
  申请人：Purdue Research Foundation

  公开号：US20170144975A1

  公开（公告）日：2017-05-25

  Triphenylethylene compounds as dual aromatase inhibitors and selective estrogen receptors modulators are described. Also described are methods for treating patients of breast cancers, and patients of breast cancer comorbid with osteoporosis, using the described triphenylethylence compounds or pharmaceutical formulations thereof.

  描述了三苯乙烯化合物作为双重芳香化酶抑制剂和选择性雌激素受体调节剂。还描述了使用所述三苯乙烯化合物或其药物制剂治疗乳腺癌患者和乳腺癌合并骨质疏松症患者的方法。
• Design and Synthesis of Norendoxifen Analogues with Dual Aromatase Inhibitory and Estrogen Receptor Modulatory Activities
  作者：Wei Lv、Jinzhong Liu、Todd C. Skaar、David A. Flockhart、Mark Cushman

  DOI：10.1021/jm501218e

  日期：2015.3.26

  Both selective estrogen receptor modulators and aromatase inhibitors are widely used for the treatment of breast cancer. Compounds with both aromatase inhibitory and estrogen receptor modulatory activities could have special advantages for treatment of breast cancer. Our previous efforts led to the discovery of norendoxifen as the first compound with dual aromatase inhibitory and estrogen receptor binding activities. To optimize its efficacy and aromatase selectivity versus other cytochrome P450 enzyme, a series of structurally related norendoxifen analogues were designed and synthesized. The most potent compound, 4'-hydroxynorendoxifen (10), displayed elevated inhibitory potency against aromatase and enhanced affinity for estrogen receptors when compared to norendoxifen. The selectivity of 10 for aromatase versus other cytochrome P450 eniymes was also superior to norendoxifen. 4'-Hydroxynorendoxifen is therefore an interesting lead for further development to obtain new anticancer agents of potential value for the treatment of breast cancer.
• A novel tamoxifen derivative, ridaifen-F, is a nonpeptidic small-molecule proteasome inhibitor
  作者：Makoto Hasegawa、Yukari Yasuda、Makoto Tanaka、Kenya Nakata、Eri Umeda、Yanwen Wang、Chihiro Watanabe、Shoko Uetake、Tatsuki Kunoh、Masafumi Shionyu、Ryuzo Sasaki、Isamu Shiina、Tamio Mizukami

  DOI：10.1016/j.ejmech.2013.11.009

  日期：2014.1

  In a survey of nonpeptide noncovalent inhibitors of the human 20S proteasome, we found that a novel tamoxifen derivative, RID-F (compound 6), inhibits all three protease activities of the proteasome at submicromolar levels. Structure activity relationship studies revealed that a RID-F analog (RID-F-S*4, compound 25) is the smallest derivative compound capable of inhibiting proteasome activity, with a potency similar to that of RID-F. Kinetic analyses of the inhibition mode and competition experiments involving biotin-belactosin A (a proteasome inhibitor) binding indicated that the RID-F derivatives interact with the protease subunits in a different manner. Culturing of human cells with these compounds resulted in accumulation of ubiquitinated proteins and induction of apoptosis. Thus, the RID-F derivatives may be useful lead chemicals for the generation of a new class of proteasome inhibitors. (C) 2013 Elsevier Masson SAS. All rights reserved.
• Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism
  作者：Nermin S. Ahmed、Nehal H. Elghazawy、Ahmed K. ElHady、Matthias Engel、Rolf W. Hartmann、Ashraf H. Abadi

  DOI：10.1016/j.ejmech.2016.02.026

  日期：2016.4

  Tamoxifen (TAM) is a widely used drug in the prophylaxis and treatment of breast cancer. TAM is metabolized to the more active 4-hydroxytamoxifen (4-OH-TAM) and endoxifen by cytochrome P450 (CYP) mainly CYP2D6 and CYP3A4 enzymes. Due to the genetic polymorphisms in CYP2D6 genes, high variation in the clinical outcomes of TAM treatment is observed among women of different populations. To address this issue, novel TAM analogues with possible altered activation pathways were synthesized. These analogues were tested for their antiproliferative action on MCF-7 breast cancer cell lines as well as their binding affinity for estrogen receptor (ER) ER-alpha and ER-beta receptors. These entire novel compounds showed better antiproliferative activity than did TAM on the MCF-7 cells. Moreover, compound 10 exhibited a half maximal growth inhibition (GI(50)) that was 1000 times more potent than that of TAM (GI(50) < 0.005 mu M vs 1.58 mu M, respectively). Along with a broad spectrum activity on various cancer cell lines, all the TAM analogues showed considerable activity on the ER-negative breast cancer cell line. For further study, compound 10 was incubated in human liver microsomes (HLM), human hepatocytes (hHEP) and CYP2D6 supersomes. The active hydroxyl metabolite was detected after incubation in HLM and hHEP, implicating the involvement of other enzymes in its metabolism. These results prove that this novel series of TAM analogues might provide improved clinical outcomes for poor 2D6 metabolizers. (C) 2016 Elsevier Masson SAS. All rights reserved.
• US9845295B2
  申请人：——

  公开号：US9845295B2

  公开（公告）日：2017-12-19